retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple Agonism Based Therapies for

Like all GLP-1 medications, oral semaglutide can cause side effects, primarily affecting the gastrointestinal system

Muscle loss alongside fat loss, leading to fatigue and reduced strength if protein intake and resistance training arent prioritized Digestive side effects such as nausea, bloating, and constipation, which can affect nutrition if meals are skipped rather than adjusted Weight regains after stopping the medication, since appetite-suppressing effects fade once treatment ends a pattern also discussed in Part 1s FAQ section The ongoing need for exercise and adequate protein throughout treatment, not just before or after it, to protect long-term metabolic health These medicines should not be viewed as a short-term fix

This is absolutely terrifying, said McGowan, who wasnt involved with the research

Research advancements have led to development of improved senolytic peptides with enhanced efficacy compared to first-generation FOXO4-DRI

Frequently Asked Questions Which form of glutathione is best for oral supplements